PDC and chronic kidney disease: Furthermore, blocking VHL and HIF-α interaction can enhance HIF-α and target genes, a viable approach for CKD anemia treatment by enhancing endogenous EPO.517,518 Compared to PHD inhibitors, VHL inhibitors may effectively prevent off-target effects unrelated to HIF signaling.